Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14–skipping mutation: A series of 6 cases

Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced Non Small Cell Lung Cancer with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018.

(2020) Florian Guisier et al.   Journal of Thoracic Oncology

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

(2020) Alexander Drilon et al.   NATURE MEDICINE

Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations

(2020) Caiwen Huang et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

(2020) Paul K. Paik et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations

(2020) Diego Kauffmann-Guerrero et al.   Oncology Research and Treatment

The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping

(2020) Ravi Salgia et al.   CANCER TREATMENT REVIEWS

Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date

(2020) Olivier Bylicki et al.   OncoTargets and Therapy

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

(2019) J Mazières et al.   ANNALS OF ONCOLOGY

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis

(2019) Mark M. Awad et al.   LUNG CANCER

Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial

(2019) Lorenza Landi et al.   CLINICAL CANCER RESEARCH

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial

(2019) D Moro-Sibilot et al.   ANNALS OF ONCOLOGY

MET Expression in Advanced Non–Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy

(2018) Henning Reis et al.   Clinical Lung Cancer

Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis

(2018) Huy Gia Vuong et al.   LUNG CANCER

PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET exon 14 Altered Lung Cancers

(2018) J K Sabari et al.   ANNALS OF ONCOLOGY

Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer

(2018) Terry L. Ng et al.   CANCER

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

(2017) Leora Horn et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

(2016) Alexa B. Schrock et al.   Journal of Thoracic Oncology